To buy or to build?

Until now, banks have focused on developing their own in-house technology to support their rapidly expanding credit derivatives business. However, a number of off-the-shelf solutions are now available. James Kemp considers the ‘buy or build’ dilemma

pg20-kemp-gif

The past four years have seen growth in the global credit derivatives market consistently overtake predictions. According to the British Bankers’ Association’s Credit Derivatives Report, the market exceeded expectations by over €150 billion in 2004 and is likely to continue expanding strongly, rising to €6.4 trillion by the end of 2006. Market growth has brought with it an increase in the range of more complex products traded, as well as greater volumes of vanilla products. These

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Chartis RiskTech100® 2024

The latest iteration of the Chartis RiskTech100®, a comprehensive independent study of the world’s major players in risk and compliance technology, is acknowledged as the go-to for clear, accurate analysis of the risk technology marketplace. With its…

T+1: complacency before the storm?

This paper, created by WatersTechnology in association with Gresham Technologies, outlines what the move to T+1 (next-day settlement) of broker/dealer-executed trades in the US and Canadian markets means for buy-side and sell-side firms

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here